Advertisement

News From the 2020 Multidisciplinary Head and Neck Cancers Symposium


This week, we’ll hear from two researchers on findings presented at the 2020 Multidisciplinary Head and Neck Cancers Symposium. We’ll also review the FDA’s approval of isatuximab-irfc as part of a triplet regimen for patients with relapsed or refractory multiple myeloma.




Advertisement
Advertisement

Advertisement




Advertisement